Evidence map›Paper›PMID 38430319›Full record

ReviewClinical & experimental metastasis2024

From pre-clinical to translational brain metastasis research: current challenges and emerging opportunities.

Emilija Aleksandrovic, Siyuan Zhang, Dihua Yu

Open access · greenAbstract readReview
In one paragraph

Review in Clinical & experimental metastasis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Emilija AleksandrovicDepartment of Pathology, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, 6001 Forest Park Rd, Dallas, TX, 75235, USA.
Siyuan ZhangDepartment of Pathology, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, 6001 Forest Park Rd, Dallas, TX, 75235, USA. Siyuan.Zhang@UTSouthwestern.edu.
Dihua YuDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. dyu@mdanderson.org.
The University of Texas Southwestern Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic StrategiesR01CA266099 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Dihua Yu · 2022 to 2026
$2.6M
Inhibition of brain metastasis by blocking MAPK12 driver kinase functionsR01CA208213 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YU, DIHUA · 2017 to 2021
$2.4M
Neural Niche in Promoting Brain Metastatic Tumor ProgressionR01CA255064 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ZHANG, SIYUAN · 2021 to 2025
$2.3M
Combating Breast Cancer Brain Metastasis by Blocking the Two-Pronged Driver Kinase Function of CDK5R01CA231149 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YU, DIHUA · 2019 to 2023
$2.3M
Mechanisms of neuroinflammation in brain metastasis progressionR01CA222405 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ZHANG, SIYUAN · 2018 to 2022
$2.2M
Prevention of Brain Metastasis Relapse through Modulation of Age-related Gut Microbiota-Immune Cross talkR21CA263798 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ZHANG, SIYUAN · 2021 to 2022
$400k
Cancer Prevention and Research Institute of Texas RR220024METAvivor 56675NCI NIH HHS R01 CA208213NCI NIH HHS R01 CA222405NCI NIH HHS R01 CA231149NCI NIH HHS R01 CA255064NCI NIH HHS R01 CA266099NCI NIH HHS R21 CA263798NIH HHS R01CA222405NIH HHS R01CA266099
6 · The paper itself

Abstract

Brain metastasis, characterized by poor clinical outcomes, is a devastating disease. Despite significant mechanistic and therapeutic advances in recent years, pivotal improvements in clinical interventions have remained elusive. The heterogeneous nature of the primary tumor of origin, complications in drug delivery across the blood-brain barrier, and the distinct microenvironment collectively pose formidable clinical challenges in developing new treatments for patients with brain metastasis. Although current preclinical models have deepened our basic understanding of the disease, much of the existing research on brain metastasis has employed a reductionist approach. This approach, which often relies on either in vitro systems or in vivo injection models in young and treatment-naive mouse models, does not give sufficient consideration to the clinical context. Given the translational importance of brain metastasis research, we advocate for the design of preclinical experimental models that take into account these unique clinical challenges and align more closely with current clinical practices. We anticipate that aligning and simulating real-world patient conditions will facilitate the development of more translatable treatment regimens. This brief review outlines the most pressing clinical challenges, the current state of research in addressing them, and offers perspectives on innovative metastasis models and tools aimed at identifying novel strategies for more effective management of clinical brain metastasis.

Indexed as

Brain NeoplasmsTranslational Research, BiomedicalAnimalsBlood-Brain BarrierDisease Models, AnimalHumansMiceTumor MicroenvironmentBrainBrain immunityBrain metastasisCancer metastasisCentral nervous system (CNS)Pre-clinical brain metastasis models

Identifiers

PMID38430319
PMCPMC11456321
OpenAlexW4392347359

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.